Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
10x Genomics Inc (TXG)
NASDAQ:TXG
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.46Last Year’s EPS
-0.5Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 12, 2025
|% Change Since: -3.67%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Neutral
While the company experienced significant product innovation and customer adoption, challenges such as revenue decline, market uncertainties, and reduced funding from key stakeholders like NIH have created a cautious outlook. The highlights are balanced by substantial lowlights, leading to an overall neutral sentiment.Company Guidance
During the 10x Genomics Fourth Quarter and Full Year 2024 Earnings Conference Call, the company provided guidance for 2025, anticipating full-year revenue to range from $610 million to $630 million, reflecting 0% to 3% growth over 2024. They expect double-digit growth in both Chromium reactions and overall spatial revenue. The company anticipates challenges from NIH funding uncertainties, with potential impacts up to $15 million not included in the current guidance. Despite these challenges, 10x Genomics remains focused on democratizing single-cell analysis, expanding their biopharma revenue, and leveraging new product innovations. The company concluded 2024 with a total revenue of $611 million and a gross margin increase to 68% due to changes in product mix.Spatial Product Revenue Growth
Spatial product revenue increased by 33% year-over-year, driven by the launch of new products like Visium HD and Xenium Prime 5K.
Gross Margin Improvement
The gross margin increased to 67% in Q4 2024 from 63% in the same period of 2023, primarily due to a change in product mix.
Successful Product Launches
Major new products were launched across all three platforms in 2024, including the introduction of a new microfluidic architecture, GEM-X, and products with lower prices aimed at increasing volumes.
Positive Customer Response
New product launches, such as Visium HD and Xenium Prime 5K, have been met with exceptional feedback and growing customer adoption.
Reduced Operating Loss
Operating loss decreased to $194.6 million in 2024 compared to a loss of $265.3 million in 2023.
Strong Balance Sheet
Ended 2024 with $393.4 million in cash and marketable securities, an increase from the previous year.
---
TXG Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TXG Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 12, 2025 | $12.00 | $11.94 | -0.50% |
| Oct 29, 2024 | $15.79 | $16.49 | +4.43% |
| Aug 08, 2024 | $19.55 | $20.43 | +4.50% |
| Apr 30, 2024 | $29.28 | $26.92 | -8.06% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does 10x Genomics Inc (TXG) report earnings?
10x Genomics Inc (TXG) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is 10x Genomics Inc (TXG) earnings time?
10x Genomics Inc (TXG) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TXG EPS forecast?
TXG EPS forecast for the fiscal quarter 2025 (Q1) is -0.46.
---